Development of lupus erythematosus during infl iximab treatment;Infl iximabterápia mellett jelentkezo lupus erythematosus

Orvosi Hetilap

Volumn 154, Issue 15, 2013, Pages 590-598

  Gyöngyösi, Nóra ^a   Lőrincz, Kende ^a   Kárpáti, Sarolta ^a   Wikonkál, Norbert ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anti TNFa therapy; Drug induced lupus erythematosus; Infl iximab; Psoriasis; SLE

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INFLIXIMAB; BIOLOGICAL MARKER; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CORTICOSTEROID THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; LUPUS LIKE SYNDROME; PSORIASIS; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; FEMALE; MIDDLE AGED; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; DERMATOLOGIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PSORIASIS;

MLCS; MLOWN;

EID: 84876261230     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2013.29588     Document Type: Article

References (49)

1. Chang, C., Gershwin, M. E.: Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf., 2011, 34, 357-374.
2. Marzano, A. V., Vezzoli, P., Crosti, C.: Drug-induced lupus: an update on its dermatologic aspects. Lupus, 2009, 18, 935-940.
3. Fry, L., Baker, B. S.: Triggering psoriasis: the role of infections and medications. Clin. Dermatol., 2007, 25, 606-615.
4. Reich, K., Burden, A. D., Eaton, J. N., et al.: Efficacy of biologics in th e treatment of moderate to severe psoriasis: a network meta-Analysis of randomized controlled trials. Br. J. Dermatol., 2012, 166, 179-188.
5. Viguier, M., Pagès, C., Aubin, F., et al.: Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br. J. Dermatol., 2012, 167, 417-423.
6. Bagel, J., Lynde, C. , Tyring, S., et al.: Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J. Am. Acad. Dermatol., 2012, 67, 86-92.
7. Atteno, M., Peluso, R., Costa, L., et al.: Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previou s disease-modifying antirheumatic drugs. Clin. Rheumatol., 2010, 29, 399-403.
8. Barker, J., Hoffmann, M., Wozel, G., et al.: Efficacy and safety of infliximab vs. methotrexate in patients with moderate-Tosevere plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br. J. Dermatol., 2011, 165, 1109-1117.
9. Saurat, J. H., Stingl, G., Dubertret, L., et al.: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol., 2008, 158, 558-566.
10. Saurat, J. H., Langley, R. G., Reich, K., et al.: Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br. J. Derma tol., 2011, 165, 399-406.
11. Lin, V. W., Ringold, S., Devine, E. B.: Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a bayesian network meta-Analysis. Arch. Dermatol., 2012 , 148, 1403-1410.
12. Reich, K., Signorovitch, J., Ramakrishnan, K., et al.: Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J. Am. Acad. Dermatol., 2010, 63, 1011-1018.
13. Brooklyn, T. N., Dunnill, M. G., Shetty, A., et al.: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut, 2006, 55, 505-509.
14. Uthman, I. W., Touma , Z., Sayyad, J., et al.: Response of deep cutaneous vasculitis to infliximab. J. Am. Acad. Dermatol., 2005, 53, 353-354.
15. Jacobi, A., Antoni, C., Manger, B., et al.: Infliximab in the treatm ent of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol., 2005, 52 (3 Pt 1), 522-526.
16. Sullivan, T. P., Welsh, E., Kerdel, F. A., et al.: Infliximab for hidradenitis suppurativa. Br. J. Dermatol., 2003, 149, 1046-1049.
17. Bargagli, E., Galeazzi, M., Bellisai, F., et al.: Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration, 2008, 75, 346-349.
18. Pardo, J., Mercader, P., Mahiques, L., et al.: Infliximab in the management of severe pemphigus vulgaris. Br. J. Dermatol., 2005, 153, 222-223.
19. Holló, P., Szakonyi, J., Kiss, D., et al.: Successful treatment of lichen planus with adalimumab. Acta Derm. Venereol., 2012, 92, 385-386.
20. Günther, C., Aringer, M., Lochno, M., et al.: TNF-Alpha blockade with infliximab in a patient with lupus erythematosus profundus. Acta Derm. Venereol., 2012, 92, 401-403.
21. Chang, C., Gershwin, M. E.: Drugs and auto immunity-A contemporary review and mechanistic approach. J. Autoimmun., 2010, 34, J266-J275.
22. Vedove, C. D., Del Giglio, M., Schena, D., et al.: Drug-induced lupus erythema tosus. Arch. Dermatol. Res., 2009, 301, 99-105.
23. Atzeni, F., Sarzi-Puttini, P., Dell'Acqua, D., et al.: Adalimumab clinical efficacy is assoc iated with rheumatoid factor and anticyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res. Ther., 2006, 8, R3.
24. Poulalhon, N., Begon, E., Lebbé, C., et al.: A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br. J. Dermatol., 2 007, 156, 329-336.
25. Bacquet-Deschryver, H., Jouen, F., Quillard, M., et al.: Impact of three anti-TNF-Alpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J. Clin. Immunol., 2008, 28, 445-4 55.
26. Dalle Vedove, C., Simon, J. C., Girolomoni, G.: Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF-A agents. J. Dtsch. Dermatol. Ges., 2012, 10, 889-897.
27. Atzeni, F., Turiel, M., C apsoni, F., et al.: Autoimmunity and anti-TNF-Alpha agents. Ann. N. Y. Acad. Sci., 2005, 1051, 559-569.
28. Zirwas, M. J., Kress, D. W., Deng, J. S.: The utility of antihistone antibody screening in the diagnosis of drug-induced lupus erythematosus. Arch. Dermatol., 2004, 140, 494-495.
29. De Bandt, M., Sibilia, J., Le Loët, X., et al., Club Rhumatismes et Inflammation: Systemic lupus erythematosus induced by antitumor necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther., 2005, 7, R545-R551.
30. Subramanian, S., Yajnik, V., Sands, B. E.: Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm. Bowel Dis., 2011, 17, 99-104.
31. Williams, V. L., Cohen, P. R.: TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int. J. Dermatol., 2011, 50, 619-625.
32. Cos ta, M. F., Said, N. R., Zimmermann, B.: Drug-induced lupus due to anti-Tumor necrosis factor alpha agents. Semin. Arthritis Rheum., 2008, 37, 381-387.
33. Williams, E. L., Gadola, S., Edwards, C. J.: Anti-TNF-induced lupus. Rheumato logy (Oxford), 2009, 48, 716-720.
34. Marzano, A. V., Vezzoli, P., Crosti, C.: Drug-induced lupus: an update on its dermatologic aspects. Lupus, 2009, 18, 935-940.
35. Antonov, D., Kazandjieva, J., Etugov, D., et al.: Drug-induced lupus erythematosus. Clin. Dermatol., 2004, 22, 157-166.
36. Rubin, R. L.: Drug-induced lupus. Toxicology, 2005, 209, 135-147.
37. Almoallim, H., Al-Ghamdi, Y., Almaghrabi, H., et al.: Anti-Tumor necrosis factor-A induced systemic lupus erythematosus. Open Rheumatol. J., 2012, 6, 315-319.
38. Vasoo, S.: Drug-induced lupus: an update. Lupus, 2006, 15, 757-761.
39. Stokes, M. B., Foster, K., Markowitz, G. S., et al.: Development of glomerulonephritis during anti-TNF-Alpha therapy for rheumatoid arthritis. Nephrol. Dial. Transplant., 2005, 20, 1400-1406.
40. Chadha, T., Hernandez, J. E.: Infliximab-relate d lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum., 2006, 55, 163-166.
41. Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., et al.: Autoimmune diseases induced by TNF-Targeted therapies: analysis of 233 cases. Medicine (Baltimore), 2007, 86, 242-251.
42. Wetter, D. A., Davis, M. D.: Lupus-like syndrome stributable to anti-Tumor necrosis factor a therapy in 14 patient during an 8-year period at Mayo Clinic. Mayo Clin. Proc., 2009, 84, 979-984.
43. Ye, C., Sholter, D., Martin, L., et al.: Successful switch of patients with rheumatoid arthritis developing anti-Tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agent. J. Rheumatol., 2011, 38, 1216. Author reply 1217-1218.
44. Wil liams, V. L., Cohen, P. R.: TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int. J. Dermatol., 2011, 50, 619-625.
45. Puertas-Abreu, E., P olanco, E. R., Azocar, M., et al.: Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-A. Int. Arch. Med., 2012, 5, 7. Doi: 10.1186/1755-7682-5-7.
46. Sifuentes Giraldo, W. A, Ahijsn Lana, M., Garc? a Villanueva, M. J., et al.: Chilblain lupus induced by TNF-A antagonists: a case report and literature review. Clin. Rheumatol., 2012, 31, 563-568.
47. Pink, A. E., Fonia, A., Allen, M. H., et al.: Antinuc lear antibodies associate with loss of response to antitumour necrosis factor-Alpha therapy in psoriasis: a retrospective, observational study. Br. J. Dermatol., 2010, 162, 780-785.
48. Iwata, D., Namba, K., Mizuuchi, K., et al.: Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab. Graefes Arch. Clin. Exp. Ophthalmol., 2012, 250, 1081-1087.
49. Jókai, H., Szakonyi, J., Kontár, O., et al.: Cutaneous lymphocyteassociated antigen as a novel predictive marker of TNF-Alpha inhibitor biological therapy in psoriasis. Exp. Dermatol., 2013., 22, 221-223.